Research programme - plectasin antibacterials - Adenium Biotech

Drug Profile

Research programme - plectasin antibacterials - Adenium Biotech

Alternative Names: AP 114; AP 138

Latest Information Update: 22 Jan 2014

Price : $50

At a glance

  • Originator Novozymes A/S
  • Developer Adenium Biotech; Novozymes A/S
  • Class Peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections
  • Research Gram-positive infections

Most Recent Events

  • 01 Dec 2013 Early research in Gram-positive infections in Denmark (unspecified route)
  • 01 Dec 2013 Preclinical trials in Clostridium infections in Denmark (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top